Levetiracetam is a new anti-convulsant with impressive pivotal trial credentials. We examined its effectiveness in refractory clinic patients with epilepsy with a year's follow up. Six months after initiation 32% of the patients were seizure free, and 26% at one year.
INTRODUCTION
The aim of epilepsy care is to render people with the condition seizure free-it is only seizure freedom that saves lives and prevents sudden death in epilepsy. Seizure freedom also brings improvement in morbidity and in quality of life. Unfortunately clinical trials of new antiepileptic drugs concentrate on measuring 50% reductions in seizure frequency (admirable but of little use to the patient) and also are short term, not usually longer than 18-20 weeks. Clinical trials therefore concentrate on short-term improvement and side effects and tell us very little else (and are designed purely to get the drug to the market). There is a need, therefore, to explore the use, benefits and drawbacks of antiepileptic drugs once they have reached the market. We present the results of a year's follow up of a new anti-convulsant drug, Levetiracetam, in a clinical setting, measuring the number of patients that became seizure free and those that remained seizure free, the number of patients who did not gain benefit (or only limited benefit) from the drug and whether any positive gains from the drug were only short-term, or whether they lasted.
Patients usually enrolled in clinical trials in the UK are pharmaco-resistant anyway, since they have usually been exposed to most of the existing anticonvulsant drugs. An audit of a drug's clinical use may give a clearer picture of those patients that may respond to the new drug. Once a drug is licensed it also becomes the clinician's responsibility whether to use it strictly within the licence or whether its use can be extended out of the licence to types of epilepsy not currently covered by it. This has always been our policy. In judging the effect of a new drug in a clinic it also has to be remembered that the first drug tried in the patient is the one most likely to work, if chosen correctly, and there is a law of diminishing return as other drugs are tried. After successive failures with other drugs, there is a diminishing likelihood that the patient will become seizure free 1, 2 . A drug that does create seizure freedom in a substantial proportion of pharmaco-resistant patients, which is then maintained, would be very valuable in a clinic population where disappointment with new medication is the rule.
Levetiracetam is the S-enantioner of a pyrrolidone derivative and is structurally similar to Piracetam, a drug used in the UK for resistant myoclonic seizures. Interestingly Levetiracetam failed the usual animal screening tests for antiepileptic activity but has been shown in other pre-clinical tests to be a powerful anti-convulsant with some evidence of neuroprotection and seems active against animal models of both partial and generalised epilepsy 3 .
Although the drug has a unique specific binding site in the brain 4 , its mode of action is unknown. It certainly appears to have no effect on GABA or sodium transport mechanisms and is therefore different from most antiepileptic drugs. Animal studies have shown little acute or chronic toxicity and no evidence of teratogenesis. In man there is rapid absorption after oral ingestion, steady state is reached in 48 hours, it has linear kinetics and only 10% plasma protein binding and is renally excreted. There appear to be no drug interactions; twice daily dosage is acceptable because brain retention is much longer than its rather short half-life. It has a fairly unique pharmaco-kinetic profile and theoretically should be easy to use 5 .
There have been three pivotal double-blind placebo controlled trials, which showed a definite doseresponse curve in seizure control significantly superior to the placebo. A total of 8% of patients receiving the higher dose of Levetiracetam (3 g total daily dose) became seizure free. Simple partial, complex partial and secondary generalised seizures all showed a significant response to Levetiracetam with a rapid and sustained clinical improvement over the fairly short term of the trials 6 . Would the apparent ease of use and impressive efficacy in double-blind controlled trials hold up in actual clinical practice? A study of the long-term continuation (retention) rate, efficacy and safety data was made of all patients with epilepsy exposed to the drug during its developmental program 7 . The retention rate in this study was 60% after 1 year and 32% after 5 years: 13% of patients became seizure free for at least 6 months. We decided to examine the seizure freedom and retention rate in a population of patients in our clinic, with mixed epilepsy diagnoses, given the drug and followed for a year. We also looked at the drop out rate and the reason why patients dropped out.
METHOD
Levetiracetam became available for clinical use in the UK in October 2000 with a licence restricting its use to resistant partial onset epilepsy with or without secondary generalisation. However we extended its use (because of previous clinical experience) to patients with resistant primary generalised epilepsy.
RESULTS
The records of 120 patients with resistant epilepsy, either partial onset or primary generalised, who were offered the drug in our clinic, between October 2000 and August 2001 were scrutinised. A note was made of diagnosis and seizure frequency before Levetiracetam was added, reduction in seizure frequency at 6 and 12 months after the introduction of Levetiracetam, side effects, whether the patient was still taking the drug at 6 and 12 months (and if not what the reason was for withdrawal) and maximum dosage used at 6 and 12 months.
One hundred and twenty patients came into ascertainment but, for reasons that were unclear, one patient, though slated to receive Levetiracetam, never started on it. One patient dropped out after only two doses but is included in the audit: 119 patients are therefore included in the results. Fig. 1 shows changes in seizure frequency at 6 months and at 1 year for the whole group as a percentage, divided into epilepsy types. Of the group as a whole 32% were seizure free at 6 months and 26% were seizure free at 1 year. Fig. 2 shows those patients withdrawing from Levetiracetam at 6 and 12 months. Twenty-one patients had withdrawn by 6 months (two with more than one reason) and 27 patients had withdrawn by 1 year (one with multiple reasons). The intolerable side effects (at 6 and 12 months), which had lead to patient withdrawal, are shown in Table 1 . Ninety-eight patients were still taking the drug at 6 months, although some had side effects that they felt were tolerable; these are shown in Table 2 . Ninety-two patients were still taking Levetiracetam at the end of 12 months. Some patients had more than one side effect. (2); increase in seizures when VPA withdrawn (1); due to stress (1); unexplained reduction in seizure frequency (2). Table 5 : Seizure frequency after 12 months for patients not seizure free at 6 months (n = 60).
Seizure frequency at 12 months (compared to 6 months, %) Table 3 shows the mean dose of Levetiracetam given to patients who were seizure free at 6 months and at 1 year. Tables 4 and 5 examine those patients who were seizure free at 6 months and whether they were still seizure free at 12 months and if not, possible reasons for return of seizures. Most seem to lose their seizure control when concomitant medication was withdrawn, although one patient had to withdraw from Levetiracetam, even though he had achieved seizure control with it, because of side effects, which he felt were intolerable.
Of the 98 patients who continued with Levetiracetam beyond 6 months, 60 at that time were not seizure free. Most retained the same degree of seizure control as they had had at 6 and 12 months but were not seizure free. Six had better control than at 6 months (of whom three at 12 months were now seizure free). Five patients had worse seizure control at 12 months than they had had at 6 months and are in the process of withdrawing from the drug.
DISCUSSION
All of these patients, as would be expected with the introduction of a new antiepileptic drug, can be classed as being fairly resistant to medication. All of the partial onset seizure patients had tried at least four other antiepileptic drugs before Levetiracetam was instituted and most were on two antiepileptic drugs at the time Levetiracetam was given to them. The primary generalised group had all failed to gain control with at least Sodium Valproate, Lamotrigine and a Benzodiazepine: many had taken other drugs as well.
The initial seizure freedom rate is therefore, in this group of refractory patients, surprising. Although there is not a 100% retention rate at 12 months, in terms of seizure freedom, 74% of the patients who were seizure free at 6 months remained seizure free at 12 months. A small number of patients, who were not seizure free at 6 months have become seizure free by 12 months. Overall, in terms of the total group who started to take Levetiracetam, 26% have been seizure free for a year and are therefore eligible for a driving licence, have an improved quality of life, and, of course, are free of the risk of sudden death in epilepsy, which is high in this population of patients with refractory epilepsy.
We intend to follow this group of patients to see if this retention rate is maintained and enlarge our experience of how to use this drug. Like most clinicians we now tend to start it with a lower starting dose and a slower increment in dosage than currently recommended by the manufacturers. This, in itself, may reduce the small number of patients who drop out because of intolerable side effects. Our data suggests that the clinician will learn fairly quickly whether the drug had been effective or not, and, if it is effective, that effectiveness will tend to stay for at least a year. We are also continuing to audit our use of the drug outwith its current license, particularly in Juvenile Myoclonic Epilepsy and photo and pattern sensitivity, for which it seems extremely effective 8, 9 .
Our initial experience with this drug is favourable. Because of its impressive and sustainable seizure freedom rate, its comparatively low side effect profile and its lack of interactions with other medication plus the finding from this audit that one knows pretty quickly whether it is going to be effective or not, in our clinic we have positioned it as the rational first add on drug if the initial monotherapy drug fails. Formal trials in primary generalised epilepsy, photo and pattern sensitivity and as an initial monotherapy drug are clearly very necessary.
